

June 19-20, 2018
Paris, FranceJohn Ignatius, J Clin Gastroenterol Hepatol 2018, Volume: 2
DOI: 10.21767/2575-7733-C1-002

MANAGEMENT OF *HELICOBACTER PYLORI* IN THE ERA OF POTASSIUM-COMPETITIVE ACID BLOCKER

John Ignatius G Ledesma

Riverside Medical Center, Philippines

The most widely prescribed regimen for first-line *H. pylori* eradication has been a triple therapy with proton pump inhibitor (PPI) and 2 antibiotics. However, the eradication rate of PPI-based regimen has been declining over the years, mainly due to resistance to antibiotics. To exert sufficient *H. pylori* killing effect of antibiotics, maintenance of intragastric pH around 6 to 7 is mandatory. Development of potent gastric acid secretion-lowering agents should improve the eradication rate. Potassium-competitive acid blocker (PCAB) possess approximately 350 times more potent inhibitory effects than typical PPIs, works immediately, and the effect lasts for a long time. Additionally, metabolic elimination is independent of cytochrome P450 (CYP) 2C19 polymorphism, which is distinct from PPI. This new agent is expected to offer clinical advantages over conventional PPI-based eradication therapies.

Biography

John Ignatius G Ledesma is the head of the GI Endoscopy unit of Riverside Medical Center, Bacolod City, Philippines. He completed his Postgraduate training at the Makati Medical Center where he was awarded the most outstanding intern and most outstanding chief resident. He was the Chief of fellows and by far the only Research Fellow in Gastroenterology. He has been a speaker in over 250 local, national and international scientific meetings. He is the recipient of over a dozen awards of distinction, recognition, achievement, services and most recently, The Canlaon Medical Society most outstanding Physician of 2017.

drjohnignatiusledesma@yahoo.com